Clinical Trials Logo

Relapsed Fallopian Tube Cancer clinical trials

View clinical trials related to Relapsed Fallopian Tube Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01940172 Completed - Clinical trials for Relapsed Fallopian Tube Cancer

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Start date: November 2013
Phase: Phase 1
Study type: Interventional

This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.